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treatment series, the INCAT score decreased significantly in 
all 10 patients. Four of these 14 patients were treated in out-
patient clinics using long-term maintenance IA with 1–2 
treatments per week. In these 4 patients, effects of long-
term maintenance IA resulted in an improvement of overall 
disability. In all patients, IA was safe, well tolerated, and no 
severe adverse effects occurred.  Conclusion: IA could be an 
effective and safe option for CIDP patients with unsatisfac-
tory response to first-line treatment options and for long-
term maintenance treatment. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 First observations of recurrent corticosteroid-respon-
sive polyneuropathies led to the definition of chronic 
 inflammatory demyelinating polyradiculoneuropathy 
(CIDP) as an immune-mediated disorder in 1958  [1, 2] . 
CIDP thus is a relatively new entity which has been dif-
ferentiated from the acute form, known as Guillain-Bar-
ré syndrome (GBS) which was first described in 1916  [3] . 
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 Abstract 
 Background/Aims: First-line treatment options for chronic 
inflammatory demyelinating polyradiculoneuropathy (CIDP) 
are corticosteroids, intravenous immunoglobulin, and plas-
ma exchange. In a significant number of patients, first-line 
therapy fails, and long-term maintenance treatment still re-
mains a therapeutic challenge. Immunoadsorption (IA) may 
be an alternative to classical plasma exchange in the therapy 
of immune-mediated neurologic diseases. The aim of this 
investigation was to evaluate efficacy and safety of IA in pa-
tients with CIDP with unsatisfactory response to first-line 
treatment options.  Methods: CIDP patients received adjunct 
IA treatment using tryptophan-immune adsorbers. The in-
flammatory neuropathy cause and treatment disability (IN-
CAT) score was used to grade disability and monitor treat-
ment effects.  Results: In total, 14 CIDP patients were ana-
lyzed. Ten patients were treated in hospital. After one IA 
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The classic presentation is characterized by progressive 
or relapsing symmetrical motor or sensory symptoms, 
developing over more than 2 months, elevated cere-
brospinal fluid (CSF) protein levels and heterogeneous 
slowing of nerve conduction velocities. In addition to the 
classic presentation, a spectrum of CIDP variants exists, 
with distribution of symptoms including predominantly 
distal forms, asymmetric, multifocal, and pure sensory 
forms  [4] . CIDP is associated with substantial morbidity 
and even mortality. Although defined diagnostic criteria 
for CIDP are meanwhile increasingly sensitive and spe-
cific  [5–7] , there is still significant overlap between CIDP 
and other neuropathies, sometimes leading to underdi-
agnosis of the disorder. The estimated prevalence for the 
disease varies from 1 to 8.9 per 100,000; the reported in-
cidence rate is 1.6/100,000/year  [8–10] . 
 The pathogenesis of CIDP still remains to be fully elu-
cidated; however, it is generally accepted that CIDP is an 
immune-mediated disorder with dysfunctions on the hu-
moral and cellular level  [11] . Cell-mediated and humoral 
immune responses directed against peripheral nerve an-
tigens cause organ-specific damage, which is a classical 
feature of an autoimmune disease. Passive transfer ex-
periments have revealed that serum or purified immuno-
globulin G from CIDP patients can induce marked con-
duction block and demyelination in rat nerves thus sup-
porting the importance of antibodies in the pathogenesis 
 [12] . Myelin protein zero, gangliosides, and related glyco-
lipids have been identified as putative target antigens  [4] . 
 Early and effective treatment of CIDP is important to 
minimize or prevent axonal degeneration, which occurs 
secondary to demyelination. Responses to immunomod-
ulation with corticosteroids, intravenous immunoglobu-
lin (IVIG), and plasma exchange (PE) have been con-
firmed in trials, suggesting no difference in efficacy 
among these three therapies in reducing impairment at 
least temporarily  [7, 13–17] . If there is no response to 
these three first-line therapeutic options, which occurs in 
20–40% of patients, switching between treatments can 
increase the overall number of responders considerably 
 [4, 13] . If the response is inadequate or maintenance dos-
es of the initial treatment are high, combination of treat-
ments should be considered as well as adding an im-
munosuppressant or immunomodulatory drug  [18–20] . 
According to current guidelines, treatment must be con-
tinued in responding patients until maximum improve-
ment or stabilization occurs  [20] . Long-term mainte-
nance treatment still remains a challenge. Both PE and 
IVIG are possible long-term treatments usually in com-
bination with immunosuppressive drugs  [21, 22] .
 Selective immunoadsorption (IA) seems to be an 
equivalent alternative to classical PE in several neuroim-
munological diseases, e.g. GBS and myasthenia gravis 
 [23–29] due to its similar efficacy and advantageous safe-
ty profile avoiding substitution of human plasma prod-
ucts. However, a randomized clinical trial comparing 
these treatment options is currently not available. Al-
though there are no direct comparisons between PE and 
IA in patients with CIDP, studies comparing the two 
treatments have been conducted in glomerulonephritis 
 [30] . Immediate antibody elimination, pulsed induction 
of antibody redistribution, and immunomodulation are 
major mechanisms of action  [31] . Using PE, plasma is sep-
arated from blood cells, discarded and substituted by a 
human albumin solution or fresh frozen plasma. In the 
case of IA, however, plasma is passed through an adsorb-
er column after plasma separation, and the treated plas-
ma is then returned to the patient. With the tryptophan-
linked polyvinylalcohol IA system, immunoglobulins
including IgG and IgM and immune complexes are elim-
inated from the plasma by hydrophobic and ionic interac-
tion with the adsorber surface  [27, 32] . Tagawa et al. [33] 
revealed that the tryptophan-linked column very effec-
tively removes anti-ganglioside immunoglobulin G anti-
bodies from plasma.
 The aim of this retrospective investigation was to eval-
uate the efficacy and safety of IA in patients with CIDP 
with unsatisfactory response to first-line treatment op-
tions as well as a possible long-term treatment option for 
patients with a relapsing and chronic progressive course, 
which has not been evaluated yet.
 Material and Methods 
 In order to assess safety and efficacy of IA as a therapeutic op-
tion in CIDP patients with unsatisfactory response to first-line 
treatment options (i.e. corticosteroids, IVIG, or PE), we per-
formed a retrospective analysis of CIDP patients, who were treat-
ed in four centers. Unsatisfactory response to at least two of these 
first-line treatment options was defined as (a) when first-line 
treatment options were clinically not effective, (b) maintenance 
doses of the initial treatment were high, (c) or unfavorable side 
effects occurred. Additionally, a further criterion was adding of 
an immunosuppressant medication (e.g. azathioprine in combi-
nation with corticosteroids or azathioprine alone) as mainte-
nance therapy to achieve an improvement of symptoms related to 
CIDP.
 To confirm the diagnosis of definite CIDP, clinical symptoms, 
course of the disease, CSF compositions, and neurophysiological 
findings according to the current diagnostic guidelines were eval-
uated in all patients  [18, 20, 34, 35] . Patients with pure motor syn-
dromes were excluded. Patients with CSF cell counts of more than 
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20 cells/  l were considered to be suffering from an infectious 
polyneuropathy and therefore excluded. Neurophysiological test-
ing was routinely performed in all patients, which included elec-
tromyographic as well as electroneurographic testing for determi-
nation of the nerve conduction velocity (NCV). Patients without 
any NCV changes or conduction blocks were excluded.
 IA was performed as adjunctive therapy when patients ful-
filled the latter criteria using the tryptophan-linked polyvinyl al-
cohol adsorber TR-350, after membrane plasma separation with 
the polyethylene plasma separator OP-05W (Asahi Kasei Kuraray 
Tokyo, Japan), and in combination with the Octo Nova extracor-
poreal circuit technology (SW 4.30.2, front 4.30.0; Diamed Me-
dizintechnik, Cologne, Germany). Adsorber, plasma separator, 
and tubing system were for single use only. Vascular access was 
achieved in patients, who were treated in hospital by placement of 
a double lumen central venous catheter in the jugular or subcla-
vian vein. 
 According to the protocol of the Department of Nephrology 
of the University of Cologne, for all in-hospital IA treatments, a 
plasma treatment volume for tryptophan IA of 4 l was implement-
ed. This was achieved in practice by sequential use of two TR-350 
IA columns. Frequency of IA was individually adjusted according 
to clinical signs and fibrinogen levels. If necessary, treatment in-
tervals were extended depending on the degree of fibrinogen de-
pletion, which is caused by adsorber treatment. As assessed by 
post-IA measurement of fibrinogen levels, a substitution of fibrin-
ogen was not necessary for any patient. 
 In long-term outpatient patients, peripheral venous access
(n = 1) or arteriovenous shunt (n = 3) was used. In general, the 
plasma treatment volume for tryptophan IA is 2.0–2.5 l, which 
was used for all long-term outpatient treatments.
 Response to treatment was measured by improvement in 
strength, sensation and ability to perform activities of daily living. 
Functional disability was assessed with the inflammatory neu-
ropathy cause and treatment disability (INCAT) score  [36] (see 
 table 1 ). 
 Statistical analysis was performed using SigmaStat software 
(SigmaStat Version 3.0, SPSS Inc., Chicago, Ill., USA). The Wil-
coxon signed-rank test was used for the analysis of change in 
 INCAT score from baseline to time after IA, because variables 
could not been assumed to be normally distributed. Descriptive 
statistics are provided as mean and standard deviation.
 Results 
 We identified 14 patients with CIDP (mean age 56  8 
15 years; 6 women, 8 men) and unsatisfactory response to 
at least two first-line treatment options. Ten patients were 
treated in-hospital. Four of these 14 patients were treated 
in outpatient clinics using long-term maintenance IA 
with 1–2 treatments per week. 
 The course of the disease revealed that a remitting or 
chronic progressive course was present with a nadir of 
disease beyond 4 weeks, differentiating acute demyelin-
ating polyradiculoneuropathy (GBS) from CIDP. Clinical 
findings were compatible with progressive or relapsing 
motor and sensory dysfunction of more than one limb. 
CSF examinations were performed in all patients; an el-
evated cell count in the CSF was not observed.  Dissemi-
nated NCV reduction or conduction blocks were present 
in all cases. Electromyographic findings with pathologi-
cal spontaneous activity and neurogenic action potential 
alterations were found in all patients. Following estab-
lishment of the diagnosis CIDP, all patients were treated 
with corticosteroids, IVIG, or PE as first-line treatment. 
In all patients, the first-line treatment was clinically not 
Table 1. T he INCAT disability scale, modified from Hughes [36]
Arm disability Leg disability
0 No upper limb problems 0 Walking not affected
1 Symptoms in 1 arm or both arms not affecting ability to perform any 
of the following functions: doing all zippers and buttons, washing or 
brushing hair, using knife and fork together, handling small coins
1 Walking affected, but walks independently outdoors
2 Symptoms in 1 arm or both arms, affecting but not preventing any of 
functions listed above
2 Usually uses unilateral support (stick, single crutch,
1 arm) to walk outdoors
3 Symptoms in 1 arm or both arms, preventing 1 or 2 of functions listed 
above
3 Usually uses bilateral support (sticks, crutches, 
frame, 2 arms) to walk outdoors
4 Symptoms in 1 arm or both arms, preventing 3 or all of functions 
listed above, but some purposeful movements still possible
4 Usually uses wheelchair to travel outdoors, but able 
to stand and walk few steps
5 Inability to use either arm for any purposeful movement 5 Restricted to wheelchair, unable to stand and walk 
few steps with help
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effective, maintenance doses of the initial treatment were 
high, or unfavorable side effects occurred. 
 Ten CIDP patients with unsatisfactory response to 
first-line treatment options received in-hospital IA 
treatment in a single center between 1999 and 2009. Five 
of these patients received one series with a mean of 4.0 
 8 0.7 IA treatment sessions with a treatment volume
of 4 l plasma per session within less than 14 days. The 
other 5 patients received repeated series (range of 2–8 
series, mean 4.6  8 2.7 series) within 1–5 years. In pa-
tients with more than one IA series, the series comprised 
3–5 IA treatment sessions (mean of 3.2  8 0.5). The total 
number of IA per patient ranged between 8 and 24 treat-
ment sessions. After one IA treatment series, the INCAT 
score decreased significantly from 5.7  8 1.8 to 4.7  8 
2.0 (p = 0.004; Wilcoxon-signed rank test) in all 10
patients. In patients who received one series of IA
treatment (n = 5), clinical improvement persisted within 
a range from 4–8 weeks. All but one patient improved 
one or more points on the INCAT scale, which repre-
sented a clinically meaningful change in disability (see 
 table 2 ). 
 In the vast majority of these patients who were treated 
in hospital, adding of an immunosuppressant medication 
to corticosteroids (predominantly prednisolone) as long-
term maintenance treatment to improve clinical symp-
toms related to CIDP was necessary during the course of 
the disease (see  table 2 ). The mean corticosteroid dosage 
was 19  8 17 mg/day (range 10–50 mg), for azathioprine 
117  8 56 mg/day (range 50–150 mg).
 Four patients were treated in outpatient clinics using 
long-term IA with one (n = 3) or two (n = 1) treatments 
per week (see  table 3 ). Extension of intervals between IA 
treatments was attempted in all patients, but led to dete-
rioration of the clinical status (e.g. muscle weakness). 
Three of these 4 patients had been treated with PE prior 
to IA. In one of these patients, PE was discontinued due 
to unfavorable side effects (i.e. severe fatigue). To avoid 
repeated substitutions with human blood products, PE 
was replaced by IA in 2 patients. In all patients, long-term 
IA treatment effects resulted in improvement of overall 
disability. The INCAT score improved under long-term 
IA in all 4 patients within a range of 1–7 points. During 
long-term IA treatment, the dose of immunosuppressive 
drugs could be reduced in these 4 patients. 
 In all patients, IA was safe and well tolerated, and no 
severe side effects occurred. No adverse event occurred 
which necessitated termination of treatment. Allergic re-
actions were not observed.
 Discussion 
 In our retrospective analysis, we identified 14 CIDP 
patients with unsatisfactory response to first-line treat-
ment options. Ten of these patients were treated with one 
Table 2. C linical characteristics of CIDP patients with unsatisfactory response to first-line treatment options treated in hospital with IA
Patient
No.
Age at
diagnosis
years
Time between 
diagnosis and
start of IA, years
Number
of IA per
series
Number
of series
INCAT
score
at baseline
INCAT
score
after IA
Other treatments
before start with IA
Maintenance treat-
ment with corticoste-
roids and azathioprine
Maintenance
treatment with 
azathioprine alone
1 53 4 3 8 6 5 IVIG, CS, PE – +
2 58 1 3 7 4 3 IVIG, CS + –
3 68 4 3 3 6 5 IVIG, CS, PE + –
4 67 2 3 3 2 1 IVIG, CS * –
5 54 7 3/5 2 5 4 IVIG, CS, PE + –
6 47 <1 5 1 8 7 IVIG, CS + –
7 69 5 4 1 6 4 IVIG, CS + –
8 72 <1 4 1 5 4 IVIG, CS + –
9 75 <1 4 1 7 6 IVIG, CS – –
10 70 <1 3 1 8 8 IVIG, CS * –
Mean 63 3.6 2.8 5.7 4.7
SD 10 0.7 2.6 1.8 2.0
Median 68 3.5 1.5 6.0 4.5
C S = Corticosteroids; IVIG = intravenous immunoglobulin; PE = plasma exchange. Asterisk signifies CS alone.
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or more IA treatment series. All but one patient improved 
in the INCAT score by at least one point. The patient who 
did not change had the highest INCAT score suggesting 
a high degree of associated axonal loss, which could have 
influenced the prognosis in this patient. 
 Furthermore, we identified 4 patients who had been 
treated with long-term IA in outpatient clinics. In these 
patients, frequency of long-term IA varied from one to 
two applications per week. During long-term IA, the clin-
ical status improved in all patients without adverse ef-
fects. Before initiating IA, 3 of these 4 patients had been 
treated with PE. To avoid repeated substitutions with hu-
man blood products and due to severe side effects, PE was 
replaced by IA in these 3 patients. Preliminary data of a 
successful change from PE to IA in long-term treatment 
of CIDP had been reported previously  [37] . Successful 
long-term outpatient treatment of another immune-me-
diated neurological disorder with IA has already been de-
scribed in rare patients with severe refractory myasthenia 
gravis. In these patients, the number of myasthenic crises 
could be reduced by 89% per year by treatment with IA 
 [28] . 
 The increasing knowledge on the pathogenic rele-
vance of autoantibodies contributes to the rationale for 
IA treatment, which selectively removes antibodies in 
plasma. The presence of autoantibodies against various 
proteins and glycolipids of the peripheral nerve in serum 
and CSF from CIDP patients supports the therapeutic 
value of IA. The tryptophan-immobilized column proved 
to adsorb anti-ganglioside immunoglobulin G antibodies 
from plasma of patients with GBS and Miller-Fisher syn-
drome very effectively  [33] . Therapeutic effects of PE and 
IA in autoantibody-mediated diseases can be attributed 
to three major mechanisms: immediate intravascular re-
duction of (auto)-antibody concentration, pulsed induc-
tion of antibody redistribution, and subsequent immuno-
modulatory changes  [31] . 
 To date, more documented experience has been re-
ported with therapeutic use of PE worldwide. One reason 
is the fact that IA is not approved for clinical use in the 
USA and several other countries. In addition to regula-
tory approval, issues of reimbursement might prevent re-
cent use of IA. In Germany, selective IA has been increas-
ingly used in autoimmune-related neurological diseases 
due to its equivalent efficacy and advantageous safety 
profile  [23] . It had been shown that IA is an effective 
treatment for GBS patients  [23–25] . However, although 
IA therapy has been used as a treatment option for CIDP 
for a number of years, the efficacy of IA treatment for 
CIDP had not been analyzed in a larger number of pa-
tients yet, and only few case reports are found in the lit-
erature  [38–40] . In a small pilot trial, safety and efficacy 
of selective IA were compared with IVIG  [41] . Five CIDP 
patients receiving monthly 3 IA for 6 months showed a 
response rate of 80%. In contrast, IVIG-treated patients 
showed a response rate of 50%. Unfortunately, however, 
the study was not powered to detect a statistically signif-
icant difference between the treatment arms  [41] . In con-
trast, results of our retrospective analysis suggest that IA 
could be an effective and safe option for CIDP patients 
Table 3. C linical characteristics of CIDP patients with unsatisfactory response to first-line treatment options treated with long-term 
IA in outpatient clinics
Patient
No.
Age at
diagnosis
years
Time between
diagnosis and
start of IA, years
Number
of IA
per week
INCAT score
at baseline
before IA
INCAT
score under
long-term IA
Other treatments before start
with IA
Clinical outcome after IA
11 27 11 1 7 6 CS, IVIG,
methotrexate, PE
Improvement in strength, reduction 
in overall disability
12 31 1 2 10 5 CS, IVIG, cyclophosphamide, 
azathioprine, PE
Improvement from tetraparesis and 
wheelchair dependency to ability to 
walk, improvement in strength
13 60 3 1 8 1 CS, IVIG, cyclophosphamide, 
azathioprine
Improvement from wheelchair 
dependency to ability to walk, 
improvement in strength
14 35 3 1 4 1 CS, IVIG, cyclophosphamide, 
PE
Improvement in walking distance, 
significant improvement in strength 
of arms and legs
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with unsatisfactory response to first-line treatment op-
tions and for long-term maintenance treatment.
 In Germany, reimbursement of outpatient IA by statu-
tory health insurances requires an individual application. 
The cost of IA treatment for hospitalized patients is about 
EUR 2,300 per treatment, adding up to EUR 6,900–11,500 
for a treatment series of 3–5 IA  [42] . The cost of outpa-
tient IA treatment is essentially identical. In comparison, 
treatment with IVIG may have a higher cost  [13, 43] .
 A shortcoming of our analysis is that the optimal IA 
treatment regimen for CIDP remains to be investigated 
systematically. For CIDP patients who were treated in 
hospital, 3–5 IA treatments with a predefined treatment 
volume of 4 l within less than 14 days had significant and 
clinically relevant efficacy. The number of IA treatments 
used correlates well with other autoimmune neuropa-
thies. However, treatment volumes with the tryptophan 
adsorber were comparatively large in this study and can-
not be taken as obligatory. In other autoimmune neurop-
athies including myasthenic crisis and GBS, PE and tryp-
tophan IA were already effective with plasma treatment 
volumes of 1–2.5 l  [24, 25, 27, 40, 44, 45] . In patients treat-
ed with long-term IA, a weekly treatment volume of 2.5 l 
seems to be adequate. Therefore, the number of IA treat-
ments as well as treatment volumes should be adjusted to 
individual patients’ needs.
 In conclusion, our study demonstrates that IA can be 
regarded as an effective and safe option for the treatment 
of CIDP patients with unsatisfactory response to first-
line treatment options. Thus, IA should be considered for 
patients with unsatisfactory response to first-line treat-
ment including IVIG. Long-term maintenance treatment 
with IA proves to be an effective outpatient treatment to 
stabilize neurologic status of rare CIDP patients with un-
satisfactory response to first-line treatment options. 
However, further limitations of our investigation are the 
retrospective character and the lack of a control group; 
therefore, a larger prospective study is needed to validate 
our findings.
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